We also observed recurrent mutations in the JAK3 oncogene (13.3% vs. 5–15.3%), which is the most frequently targeted gene of the JAK-STAT pathway in T-ALL [5, 33]. Here, JAK3 is linked to acute lymphoblastic leukemia.